Department of Nursing, Faculty of Health Sciences, School for Community Health Professions, Ben-Gurion University of the Negev, P.O.B 653, 8410501, Beer-Sheva, Israel.
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Sci Rep. 2021 Sep 23;11(1):18911. doi: 10.1038/s41598-021-98245-9.
Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18-65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were - 4.2 ± 0.3 points in the oxygen-treated group and - 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] - 5.95 to - 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI - 1.00 to - 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression.Trial registration: NCT02149563 (29/05/2014).
富氧空气可能会增加脑组织中的氧气压力，并产生生化效应，即使在没有肺部疾病的患者中也是如此。一致地，几项研究表明常压氧疗在一些神经疾病中具有临床益处。这项研究检查了常压氧疗在抑郁症患者中的疗效。在一项随机、双盲试验中，从以色列南部地区招募了 55 名年龄在 18-65 岁之间、有轻度至中度抑郁症（汉密尔顿抑郁评定量表 [HRSD]评分≥8 分）的参与者。参与者在基线时接受了精神病学纳入评估，然后通过鼻管随机分配接受 35%吸入氧分数的常压氧疗或 21%吸入氧分数（室内空气），持续 4 周，在夜间进行。在研究干预开始后的基线、2 周和 4 周进行评估，使用以下工具：HRSD；临床总体印象（CGI）问卷；世界卫生组织-5 项生活质量问卷（WHO-5-QOL）；应对感量表（SOC）13 项问卷；和，Sheehan 残疾量表（SDS）。多变量回归分析显示，从基线到第 4 周，HRSD 评分的平均变化±标准差[SD]在吸氧组为-4.2±0.3 分，对照组为-0.7±0.6 分，组间差异为 3.5 分（95%置信区间[CI] -5.95 至-1.0；P=0.007）。同样，在第 4 周，CGI 评分的组间差异为 0.71 分（95% CI -1.00 至-0.29；P=0.001）。另一方面，分析显示，两组在 WHO-5-QOL、SOC-13 或 SDS 评分方面无显著差异。这项研究表明，氧疗对抑郁症的某些症状有显著的有益影响。试验注册：NCT02149563（2014 年 5 月 29 日）。
